Pulmonary arterial hypertension associated with portal hypertension

Pulmonary arterial hypertension associated with portal hypertension (also known as portopulmonary hypertension or PoPH) is a condition in which abnormally high blood pressure develops in the pulmonary arteries (the blood vessels that carry blood from the heart to the lungs) as a consequence of elevated pressure in the portal venous system, which drains blood from the gastrointestinal tract to the liver. Portal hypertension is most commonly caused by chronic liver disease and cirrhosis, but can also result from other conditions affecting the portal venous system. PoPH is classified as a form of Group 1 pulmonary arterial hypertension (PAH) and involves progressive remodeling and narrowing of the small pulmonary arteries, leading to increased resistance to blood flow through the lungs. The condition primarily affects the cardiovascular and pulmonary systems. Key symptoms include progressive shortness of breath (dyspnea), particularly during physical exertion, fatigue, chest pain, palpitations, syncope (fainting), and peripheral edema (swelling of the legs and ankles). As the disease progresses, the right side of the heart must work harder to pump blood through the narrowed pulmonary vessels, which can eventually lead to right heart failure. Patients may also exhibit signs and symptoms related to their underlying liver disease, such as ascites, jaundice, and variceal bleeding. PoPH is estimated to occur in approximately 2–6% of patients with portal hypertension. Diagnosis involves right heart catheterization to confirm elevated pulmonary arterial pressures in the setting of documented portal hypertension. Treatment includes PAH-specific therapies such as endothelin receptor antagonists (e.g., bosentan, ambrisentan, macitentan), phosphodiesterase-5 inhibitors (e.g., sildenafil, tadalafil), and prostacyclin analogues or prostacyclin receptor agonists. Liver transplantation may be considered in selected patients, particularly those with moderate PoPH who respond to medical therapy, though severe PoPH is generally considered a contraindication to liver transplantation due to high perioperative risk. Early detection and management are important to improve outcomes.

Common questions about Pulmonary arterial hypertension associated with portal hypertension